| 王俊毅,陆晓媛,经 莉,董娇娇,谷佳斐.I型子宫内膜癌组织Amot、YAP1蛋白表达与临床病理参数和预后的关系研究[J].,2023,(16):3159-3164 |
| I型子宫内膜癌组织Amot、YAP1蛋白表达与临床病理参数和预后的关系研究 |
| Study on the Relationship between Amot and YAP1 Protein Expression and Clinicopathological Parameters and Prognosis in Type I Endometrial Cancer Tissues |
| 投稿时间：2023-01-07 修订日期：2023-01-31 |
| DOI：10.13241/j.cnki.pmb.2023.16.031 |
| 中文关键词: I型子宫内膜癌 血管生成抑制素结合蛋白 Yes相关蛋白1 临床病理特征 预后 |
| 英文关键词: Type I endometrial carcinoma Angiomotin Yes-associated protein 1 Clinicopathological characteristics Prognosis |
| 基金项目:江苏省妇幼健康科研项目（F201719） |
|
| 摘要点击次数: 502 |
| 全文下载次数: 353 |
| 中文摘要: |
| 摘要 目的：研究I型子宫内膜癌（EC）组织中血管生成抑制素结合蛋白（Amot）、Yes相关蛋白1（YAP1）表达与临床病理特征和预后的关系。方法：选取自2014年01月至2017年6月期间徐州医科大学附属医院诊治的75例Ⅰ型EC患者为研究对象（EC组），以同期诊治的30例病理证实的非典型增生子宫内膜组织标本为非典型增生子宫内膜组，以30例同期经病理证实的正常子宫内膜组织标本为正常子宫内膜组。采用免疫组化法检测各组子宫内膜组织中Amot、YAP1 蛋白表达。采用Spearman秩相关性分析I型EC癌组织中Amot蛋白与YAP1蛋白表达的相关性。比较不同临床病理特征I型EC患者癌组织中Amot、YAP1 蛋白表达的差异。采用Kaplan-Meier生存曲线分析Amot、YAP1蛋白表达与I型EC患者生存预后的关系，单因素及多因素COX回归分析影响I型EC患者生存预后的因素。结果：I型EC癌组织中Amot、YAP1 蛋白阳性表达率分别为80.00%（60/75）、85.33%（64/75），明显高于非典型增生子宫内膜组织中Amot、YAP1 蛋白阳性表达率43.33%（13/30）、46.67%（14/30），差异具有统计学意义（均P＜0.05）；非典型增生子宫内膜组织中Amot、YAP1 蛋白阳性表达率明显高于正常子宫内膜组织16.67%（5/30）、20.00%（6/30），差异具有统计学意义（均P＜0.05）。I型EC癌组织中Amot与YAP1蛋白表达呈正相关（P＜0.05）。不同国际妇产科联盟（FIGO）分期、组织学分级及淋巴结转移情况I型EC患者癌组织中Amot、YAP1蛋白阳性表达率比较差异具有统计学意义（P＜0.05）。Amot阳性表达Ⅰ型EC患者累积生存时间明显低于Amot阴性表达Ⅰ型EC患者（P＜0.05）。YAP1阳性表达Ⅰ型EC患者累积生存时间明显低于YAP1阴性表达Ⅰ型EC患者（P＜0.05）。Amot蛋白阳性表达、YAP1蛋白阳性表达、FIGO分期Ⅲ期及伴淋巴结转移是影响I型EC患者不良预后的独立危险因素（P＜0.05）。结论：I型EC子宫内膜癌组织中Amot、YAP1 蛋白阳性表达升高，两者阳性表达与FIGO分期、组织学分级及淋巴结转移有关，Amot蛋白、YAP1蛋白阳性表达是影响I型EC患者预后不良的危险因素之一。 |
| 英文摘要: |
| ABSTRACT Objective: To study the relationship between the angiomotin (Amot) and Yes-associated protein 1 (YAP1) expression and clinicopathological parameters and prognosis in type I endometrial cancer (EC) tissues. Methods: 75 type I EC patients who were diagnosed and treated in Affiliated Hospital of Xuzhou Medical University from January 2014 to June 2017 were selected as the study object (EC group), 30 patients with pathologically confirmed atypical hyperplasia endometrial tissue specimens diagnosed and treated during the same period were selected as the atypical hyperplasia endometrial group, and 30 patients with pathologically confirmed normal endometrial tissue specimens during the same period were selected as the normal endometrial group. The Amot and YAP1 protein expressions in each group were detected by immunohistochemistry. Spearman rank correlation was used to analyze the correlation between Amot and YAP1 protein expression in type I EC cancer tissues. The differences of Amot and YAP1 protein expression in cancer tissues of type I EC patients with different clinicopathological characteristics were compared. Kaplan-Meier analysis (Log-rank test) was used to analyze the relationship between the expression of Amot and YAP1 protein and the survival prognosis of type I EC patients. Univariate and multivariate COX regression analysis was used to analyze the factors affecting the survival prognosis of type I EC patients. Results: The positive rates of Amot and YAP1 protein expression in type I EC tissues were 80.00%(60/75) and 85.33%(64/75), respectively, which were significantly higher than those in atypical hyperplasia endometrial tissue 43.33% (13/30) and 46.67% (14/30), and the difference was statistically significant (all P＜0.05). The positive rates of Amot and YAP1 protein in atypical hyperplasia endometrial tissue were significantly higher than those in normal endometrial tissue with 16.67% (5/30) and 20.00% (6/30), and the difference was statistically significant (all P＜0.05). There was a significant positive correlation between Amot and YAP1 protein expression in type I EC cancer tissues(P＜0.05). The positive rates of Amot and YAP1 protein expression in EC type I patients with different International Federation of Gynecology and Obstetrics (FIGO) stages, histological grades and lymph node metastasis were statistically significant (P＜0.05). The cumulative survival time of Amot-positive expression typeⅠEC patients was significantly lower than that of Amot-negative expression typeⅠEC patients (P＜0.05). The cumulative survival time of patients with YAP1-positive expression of typeⅠEC was significantly lower than that of patients with YAP1-negative expression of typeⅠEC (P＜0.05). Amot-positive expression, YAP1 positive expression, FIGO stage Ⅲ and lymph node metastasis were independent risk factors for poor prognosis in patients with EC type I (P＜0.05). Conclusion: The Amot and YAP1 protein positive expression increased in type I EC cancer tissues, which are related to FIGO stage, histological grade and lymph node metastasis. The positive expression of Amot protein and YAP1 protein is one of the risk factors affecting the poor prognosis of patients with type I EC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
